SCHEMBL1107246

SCHEMBL1107246

N#Cc1ccc(S(=O)(=O)N(CCCC(F)(F)F)c2cc3ccccc3s2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RORC P51449 6/20 0.40
NR1H2 P55055 2/20 0.40
NR1I2 O75469 1/20 0.40
RORA P35398 1/20 0.40
RORB Q92753 1/20 0.40
NR1H4 Q96RI1 1/20 0.40
KEAP1 Q14145 1/20 0.38
NFE2L2 Q16236 1/20 0.38
PSEN1 P49768 3/20 0.38
PSEN2 P49810 3/20 0.38
APH1B Q8WW43 3/20 0.38
NCSTN Q92542 3/20 0.38
APH1A Q96BI3 3/20 0.38
PSENEN Q9NZ42 3/20 0.38
ESR1 P03372 1/20 0.37
ESR2 Q92731 1/20 0.37
NR3C1 P04150 3/20 0.36
PGR P06401 1/20 0.36
POLB P06746 1/20 0.35
ALDH1A1 P00352 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1100530 0.90 RORC (0.45) RORCNR1H2ALDH1A1
SCHEMBL1107237 0.86 ESR1 (0.43) NR1I2KEAP1NFE2L2ESR1NR3C1
SCHEMBL1098737 0.84 RORC (0.46) RORCNR1H2ESR1ESR2ALDH1A1
SCHEMBL1100059 0.84 ALOX5 (0.43)
SCHEMBL1098250 0.83 ESR1 (0.39) RORCKEAP1NFE2L2ESR1ESR2
SCHEMBL12000790 0.83 ALDH1A1 (0.41) RORCKEAP1NFE2L2ESR1ESR2
SCHEMBL1107231 0.82 ESR1 (0.37) RORCNR1I2PSEN1PSEN2APH1B
SCHEMBL1100027 0.80 ESR1 (0.43) RORCNR1H2KEAP1NFE2L2ESR1
SCHEMBL1100594 0.80 ESR1 (0.43) RORCNR1H2ESR1ESR2NR3C1
SCHEMBL1098518 0.80 RORC (0.41) RORCKEAP1NFE2L2ESR1ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9434711-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, N.V. (BE) 2016-09-06 US disclosed
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-10-23 US disclosed
US-20120190674-A1 SULFONAMIDES AS TRPM8 MODULATORS BRANUM SHAWN T (US) 2012-07-26 US disclosed
US-8153682-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2012-04-10 US disclosed
US-8153682-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2012-04-10 US disclosed
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2009-10-22 US disclosed
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190674-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 RORC 3514/4885NR1H2 695/4885NR1I2 465/4885
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 RORC 3514/4885NR1H2 695/4885NR1I2 465/4885
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 RORC 3514/4885NR1H2 695/4885NR1I2 465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.